| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
PepGen Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”), Stifel, Nicolaus & Company, Incorporated (“Stifel”), Guggenheim Securities, LLC (“Guggenheim Securities”) and eac... |
| 12 Nov 2026 | 424B5 |
| 10 Nov 2026 | 424B5 |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – |
| 10 Nov 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg – |
| 06 Aug 2026 | 10-Q |
| 22 Jun 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others
Granted 34,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of PepGen Inc. (the “Company”) was held on June 18, 2026. The proposals set forth below were submitted to the stockholders at the 2026 Annual Meeting, with each such pro... |
| 22 Jun 2026 |
Form 4: Wyman Lisa, Director
Granted 34,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Resnick Joshua, Director
Granted 34,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Mayer Howard, Director
Granted 34,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Finer Mitchell H., Director
Granted 34,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Dable Habib J, Director
Granted 34,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Henson Heidi, Director
Granted 34,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Keating Laurie, Director
Granted 34,000 Stock Option (Right to Buy) |
| 26 May 2026 |
Form 4: Kasraian Kasra, Chief Technical Officer
Sold 1,233 shares ($1.74K) |
| 21 May 2026 | EFFECT |
| 21 May 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticip... |
| 19 May 2026 | CORRESP |
Loading...